Blair William & Co. IL Takes Position in Royalty Pharma PLC (NASDAQ:RPRX)

Blair William & Co. IL bought a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,801 shares of the biopharmaceutical company’s stock, valued at approximately $212,000.

Several other hedge funds have also recently made changes to their positions in the business. PNC Financial Services Group Inc. raised its position in shares of Royalty Pharma by 7.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 12,665 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 859 shares in the last quarter. Jupiter Asset Management Ltd. raised its position in shares of Royalty Pharma by 462.1% during the 1st quarter. Jupiter Asset Management Ltd. now owns 1,090,591 shares of the biopharmaceutical company’s stock valued at $33,950,000 after buying an additional 896,555 shares in the last quarter. US Bancorp DE raised its position in shares of Royalty Pharma by 41.0% during the 1st quarter. US Bancorp DE now owns 13,483 shares of the biopharmaceutical company’s stock valued at $420,000 after buying an additional 3,918 shares in the last quarter. Torray Investment Partners LLC raised its position in Royalty Pharma by 26.0% in the 1st quarter. Torray Investment Partners LLC now owns 862,018 shares of the biopharmaceutical company’s stock worth $26,835,000 after purchasing an additional 178,011 shares during the period. Finally, Pacific Capital Partners Ltd purchased a new stake in Royalty Pharma in the 1st quarter worth about $5,448,000. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on RPRX shares. Wall Street Zen raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Saturday. Citigroup increased their price objective on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, July 22nd. Finally, Morgan Stanley increased their price objective on shares of Royalty Pharma from $51.00 to $54.00 and gave the stock an “overweight” rating in a research report on Thursday, July 10th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $49.00.

Royalty Pharma Stock Performance

Royalty Pharma stock opened at $35.86 on Wednesday. The firm has a market capitalization of $20.16 billion, a P/E ratio of 20.73, a price-to-earnings-growth ratio of 2.36 and a beta of 0.55. The company’s 50-day moving average is $35.80 and its 200 day moving average is $33.66. Royalty Pharma PLC has a 1-year low of $24.05 and a 1-year high of $38.00. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.26 and a quick ratio of 1.26.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.04. The business had revenue of $578.67 million for the quarter, compared to analyst estimates of $750.06 million. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. Research analysts forecast that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.5%. Royalty Pharma’s dividend payout ratio (DPR) is 50.87%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.